NPUK is governed by its Articles and Memorandum and run by a Board of Trustees.
Our Annual Reports review our performance each year and the progress we’re making against our aims and objectives.
Our Report and Financial Statements provide a financial review each year.
01.03.21
Copenhagen, Denmark, March 1, 2021 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced the appointment of Christophe Bourdon as the company’s Chief Executive Officer, effective as of April 1, 2021, following approval from the Board of Directors...
Read more
